Entering text into the input field will update the search result below

Acura Pharma inks IMPEDE development deal with Bayer

  • Acura Pharmaceuticals (OTC:ACUR) extends a worldwide license to its IMPEDE abuse-deterrent technology to Bayer Healthcare (OTCPK:BAYRY) for use in an undisclosed methamphetamine-resistant pseudoephedrine-containing product. The companies will jointly develop it for the U.S. market.
  • Bayer also has the right to negotiate for a worldwide license to IMPEDE for additional products. Financial terms are not disclosed.
  • The IMPEDE technology platform is an advanced polymer matrix that is used in Acura's Nexafed. It is designed to limit or disrupt the extraction of pseudoephedrine from tablets.

Recommended For You

About ACUR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACUR--
Acura Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.